Semaglutide Biosimilar(Huadong Medicine/Chongqing Peg-Bio Biopharma)

在减少饮食热量摄入和增加体力活动基础上，评价采用试验药物司美格鲁肽注射液与对照药品原研司美格鲁肽注射液治疗44周后，在中国肥胖非糖尿病受试者中减重的等效性。

This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult subjects. Eligible healthy participants will be screened and randomly assigned to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or Ozempic® injection 0.25mg abdominal subcutaneous injection will be given according to their groups. Follow-up for 5 weeks after administrtion.
Studies included a screening period (up to 2 weeks), baseline, administration (single dose), and a follow-up period (5 weeks). The duration of the study will be approximately 7 weeks for a participant.